Basic Information
| LncRNA/CircRNA Name | CCDC26 |
| Synonyms | CCDC26, RAM |
| Region | GRCh38_8:128634199-129683679 |
| Ensemble | ENSG00000229140 |
| Refseq | NR_130917 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | acute myeloid leukemia |
| ICD-0-3 | NA |
| Methods | qPCR, other |
| Sample | Bone marrow samples, Mononuclear cells |
| Expression Pattern | up-regulated |
| Function Description | The upregulated expression level of CCDC26 in patients with AML was significantly associated with age, anemia, risk stratification and remission. Furthermore, patients with a high CCDC26 expression level had a poorer overall survival (P=0.0105). In addition, the area under the curve (AUC)1year and AUC2year of CCDC26 for overall survival were 0.722 and 0.686, respectively. WGCNA, PPI network and KEGG pathway analysis revealed that CCDC26 was involved in the regulation of a number of biological processes. lncRNA-CCDC26 may serve as a novel biomarker for monitoring the progression and predicting the clinical outcome of AML. |
| Pubmed ID | 31452721 |
| Year | 2019 |
| Title | lncRNA-CCDC26, as a Novel Biomarker, Predicts Prognosis in Acute Myeloid Leukemia |
External Links
| Links for CCDC26 | GenBank HGNC NONCODE |
| Links for acute myeloid leukemia | OMIM COSMIC |